Now I have enough data to calibrate. Let me finalize the review.

**Calibration anchor comparison summary:**

| Anchor | Score | Round | Comparison to HYPOGENEAGENT |
|--------|-------|-------|-----------------------------|
| scMPT | 3.40 | 1 | HYPOGENEAGENT has a more novel core idea and stronger Stage 1 benchmark, but shares similar validation weaknesses |
| GenoAgent | 4.00 | 1 | Both LLM agents for genomics, both rejected. HYPOGENEAGENT is more creative in its core concept |
| BioKGBench | 4.75 | 2 | Both about LLM agents for biomedical science, both have evaluation concerns. Similar tier |
| Gene property benchmark | 4.75 | 2 | Benchmark paper with its own evaluation concerns |
| Dictionary learning biology | 5.60 | 2 | Rejected despite interesting concept; limited validation on too few tasks |
| scDiff | 6.50 | 2 | Rejected but strong framework; had broader evaluation than HYPOGENEAGENT |
| BioDiscoveryAgent | 6.40 | 1 | Accepted. LLM agent for perturbation experiments, 6 datasets, concrete baselines. Stronger validation than HYPOGENEAGENT |
| CellPLM | 6.50 | 1 | Accepted. Single-cell pretraining, solid evaluation |

**Round 1 bracket: 3.5–6.5** (between weak reject and accept boundary)
**Round 2 narrowed: 4.0–5.0** (HYPOGENEAGENT is stronger than GenoAgent 4.0 and BioKGBench 4.75 in core novelty, but its Stage 2 validation is too thin for a 5+ score, especially compared to accepted papers like BioDiscoveryAgent 6.4 which have multi-dataset validation)

**Final score: 4.5** — The core concept is genuinely novel and the Stage 1 benchmark is thorough, but the paper cannot support its central claim due to no ground truth validation, a single preliminary dataset, and a flawed enrichment comparison. It sits in weak-reject territory between GenoAgent (4.0) and BioKGBench (4.75).

## Summary
This paper proposes HYPOGENEAGENT, an LLM-agent framework that annotates gene clusters with ranked GO hypotheses and confidence scores, then uses annotation consistency (intra-cluster agreement and inter-cluster distinctiveness) to derive a Resolution Score for selecting clustering granularity in Perturb-seq data. The paper includes a thorough Stage 1 benchmark of LLMs, prompts, and embeddings on 100 curated GOBP gene sets, and a Stage 2 application to a single K562 Perturb-seq dataset.

## Strengths
- **Novel feedback loop concept.** The idea of using LLM-generated annotation consistency to drive resolution selection is, to our knowledge, genuinely novel. Prior work (Hu et al. 2025; Wang et al. 2025; Wu et al. 2025) treats clusters as fixed; HYPOGENEAGENT feeds annotation consistency back into the hyperparameter via RS_k = w·ICS_k + (1-w)·(1-ICD_k) (Section 3.4). This turns a subjective manual step into a quantitative optimization.
- **Systematic Stage 1 benchmark.** Section 4.3 and Figures S1-S3 benchmark 5 LLM backbones, 2 prompt designs, 3 embedding methods, and a temperature sweep on 100 curated GOBP sets. This provides concrete evidence that thinking LLMs outperform non-thinking ones, confidence scores are well-calibrated against semantic similarity (Fig S3a), and the top-1 hypothesis has the highest median cosine similarity with ground truth (Fig S1d). This is more thorough than typical for agent-based biology papers.
- **Multi-hypothesis prompt design is architecturally essential.** The hypothesis prompt (Fig 1) returns 5 ranked GO terms with confidence scores, which directly enables the ICS metric. Without this, the resolution-scoring framework would be infeasible. Stage 1 validates that confidence ranking correlates with accuracy (Fig S1d).
- **Model-agnostic and extensible design.** The pipeline accepts any LLM backbone, any sentence-embedding model, and any clustering resolution grid, facilitating adoption as LLMs improve.

## Weaknesses

### Fatal
None.

### Major
- **No ground truth validation of the core claim.** The abstract claims the Resolution Score "selects clustering granularities that exhibit alignment with known pathway" and the introduction states it "recovers known perturbation effects better than modularity and silhouette criteria" (line 25). However, the results never identify any specific known pathway and test whether the selected resolution recovers it. The evaluation relies on UMAP aesthetics (Figs 3b, 4b) and internal consistency metrics. Without validation against known biological ground truth — e.g., do perturbations affecting the same pathway cluster together at the selected resolution? — the central claim is unsupported.
- **Enrichment comparison reveals disagreement, not validation.** Section 4.4.3 applies the same ICS/ICD framework to Fisher-exact GO enrichment results. The enrichment-based Resolution Score peaks at resolution 0.7 (Fig 6a caption: "the resolution score peaks at 0.7"), while HYPOGENEAGENT selects 0.4–0.5. The text then claims "the selected resolution can be 0.5 or 0.4, which is consistent with our previous selection" — this contradicts the figure. Furthermore, this comparison is between two annotation sources (LLM vs. Fisher's exact test) using the same framework, not independent validation. The Strength Finder claims "cross-method agreement" but the peaks actually differ.
- **Single dataset, acknowledged as preliminary.** The entire Stage 2 evaluation uses one K562 CRISPRi Perturb-seq dataset. The abstract itself calls this "a preliminary test." For claims about establishing "LLM agents as objective adjudicators of cluster resolution," validation on additional datasets, cell types, or synthetic data with known ground truth is needed.

### Minor
- **No robustness or reproducibility analysis.** No assessment of LLM non-determinism effects on Resolution Score, no variance across re-runs, no statistical significance testing between adjacent resolutions. The selection of r=0.4 as "optimal" (Fig 3a) is based on visual inspection of median scores.
- **No null model or component ablation.** The paper does not test what resolution random annotation text would produce, nor does it ablate ICS vs. ICD individually. Without a null baseline, it is unclear whether the Resolution Score captures genuine biological signal or the LLM's tendency to generate similar-sounding biology text.
- **Stage 1 validates annotation quality, not resolution selection quality.** Stage 1 carefully benchmarks LLMs on curated GOBP sets (AUC=0.743 for GPT-o3), but this addresses a different question than whether good annotation quality translates to good resolution selection.
- **Weight parameter w chosen without specifying objective.** Section 3.4 states w=1/3 was chosen by "a small grid search" but does not specify over what objective. If the objective was internal consistency, this risks circularity.

### Trivial
None.

## Nice-to-Haves
- Quantify computational cost (wall-clock time and API cost per resolution sweep)
- Compare against MultiK or consensus-based resolution selection approaches
- Discuss Fig S5 (w-sensitivity) results in the main text: does the ranking of resolutions change across w?
- Small expert validation: a few experts independently choosing resolution for the same dataset

## Removed Points
These points are flagged to be removed, treat them with caution:
- Harsh critic's "asymmetric comparison with traditional methods" — The comparison between a biology-informed metric and biology-agnostic metrics (silhouette, modularity) is standard practice in applied biology. The asymmetry is inherent to the comparison being made. Weakened to a nice-to-have rather than a weakness.
- Harsh critic's "Section 4.4.3 applies the same ICS/ICD framework to enrichment results and calls this a comparison with 'functional enrichment analysis'" — The paper does frame this as validation, which is problematic, but the approach itself (applying the same scoring framework to an alternative annotation source) is a reasonable analytical choice. Kept as a major weakness regarding the misleading framing and disagreement.

## Novel Insights
The core novel insight is the formalization of a feedback loop between functional annotation consistency and clustering resolution selection via ICS/ICD. This is a genuine conceptual contribution — all existing LLM-for-gene-set systems treat clusters as fixed inputs, while HYPOGENEAGENT uses annotation quality as a signal for the clustering hyperparameter itself. The multi-hypothesis prompt design that enables ICS computation is architecturally clever and the Stage 1 benchmark provides practical guidance for the bioinformatics community on LLM/prompt/embedding choices.

## Suggestions
1. **Primary:** Validate against biological ground truth. Use perturbation labels in the K562 dataset to define what "correct" resolution means (e.g., resolution that best separates perturbations by known pathway) and test whether the Resolution Score selects it.
2. Add a null baseline: run the ICS/ICD framework with random text annotations to establish the score captures genuine signal.
3. Run the pipeline multiple times with different random seeds and report variance of the selected resolution.
4. Correct the enrichment comparison analysis: either acknowledge the 0.7 vs. 0.4–0.5 disagreement and explain it, or reframe as comparing two annotation approaches rather than claiming validation.

## Reporting

**All retrieved anchors across rounds:**
- Round 1: scMPT (3.40), scKGOT (2.50), DrugAgent (2.50), Explainable medical image clustering (2.50), BioDiscoveryAgent (6.40), ZerOmics (4.67), GenoAgent (4.00), CellPLM (6.50), GeSubNet (8.00), CABINET (8.00), MMQA (8.00), LLAMBO (8.00)
- Round 2: GenoAgent (4.00), BioKGBench (4.75), Gene property benchmark (4.75), Genomics Long-Range Benchmark (5.00), Dictionary learning biology (5.60), COMET (5.75), scDiff (6.50), DNALONGBENCH (5.67)

**Round 1 bracket:** 3.5–6.5 (HYPOGENEAGENT is more novel than 3.5 papers but weaker in validation than 6+ papers)
**Round 2 narrowed:** 4.0–5.0 (comparable to GenoAgent 4.0 and BioKGBench 4.75 in validation strength, but with a more novel core idea; well below BioDiscoveryAgent 6.4 which has multi-dataset validation and concrete improvements)
**Final score: 4.5** — Genuinely novel concept with thorough Stage 1 benchmarking, but the central claim (Resolution Score selects biologically better resolutions) is unsupported due to no ground truth validation, a single preliminary dataset, and a flawed enrichment comparison that actually shows disagreement rather than agreement.

MY FINAL SCORE: <score>4.5</score>
MY FINAL DECISION: <decision>Reject</decision>